Should Patents Create Incentives for Failure?
One scholar argues that patents do not—and should not—compensate for the costs of drug development.
Challenging Drug Patents to Lower Prices
The FTC cracks down on improperly listed drug patents, challenging over 100 patent listings.
How Patents Contribute to High Drug Prices
Patents covering drugs selected for Medicare price negotiation show how patents influence drug prices.
Oh, When the Feds Go Marching-In
Marching-in could allow federal government to commercialize inventions, but at the expense of patent rights.
Headless Agency Adjudication at the Patent Office
Supreme Court approval of patent adjudication raises new questions about limits of modern agency adjudication.
The First Amendment Protects Offensive Trademarks
Supreme Court holds that government cannot discriminate against offensive trademarks.
For Hepatitis Drugs, Availability Does Not Equal Access
Is the government willing to infringe on drug patents to curb a public health crisis?
Simplicity Trumps Logical Coherence
The Supreme Court upholds its concededly “incorrect” ban on post-expiration patent royalties.
Improving Patent Quality by Reducing the Patent Office’s Backlog of Applications
Improving the patent system depends on reducing processing snarls.
Chevron Deference for the U.S. Patent and Trademark Office
Asymmetrical deference to PTO decision-making may promote pro-patent policies.
Unmasking Patent Trolls
Patent and Trademark Office proposes rule that would seek to increase transparency in patent ownership.
Evaluating the PTO’s Proposed Fee Structure
Proposed fee structure remains flawed and may contribute to the perception of a “broken” patent system.